SynteractHCR hires Bill Pierce and Richard Paul

Thursday, April 4, 2013 08:00 AM

SynteractHCR, a full-service CRO, has hired two new senior executives to support the company's growth on a global scale following its recent merger. SynteractHCR has appointed Bill Pierce as chief information officer and Richard Paul as chief medical officer and vice president medical/regulatory affairs.

As CIO, Pierce will be responsible for driving operational excellence, streamlining processes and delivering high returns for invested capital. He brings a strong foundation in the CRO industry and is very experienced across clinical data management platforms and technologies. He gained leadership experience across various industries, including his last position at INC Research as chief information officer. Previously, Pierce served as vice president both for Fidelity Investments and Goldman Sachs, among other leadership positions.

In his role as CMO, he will provide global leadership and oversight for medical safety and regulatory affairs. He brings more than 23 years of clinical research, regulatory affairs, medical safety and strategic drug development experience to his new role. Prior to joining SynteractHCR, Paul held positions with QRxPharma as executive vice president of drug development where he had global responsibility for clinical research and regulatory affairs. He also served as senior vice president of global regulatory affairs at Icon Clinical Research.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs